Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Phasebio Pharmaceuticals Inc (PHAS)

Phasebio Pharmaceuticals Inc (PHAS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,919
  • Shares Outstanding, K 48,691
  • Annual Sales, $ 10,830 K
  • Annual Income, $ -131,070 K
  • 60-Month Beta 2.05
  • Price/Sales 2.70
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade PHAS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.39
  • Most Recent Earnings -0.23 on 05/16/22
  • Next Earnings Date 08/11/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 320.43% ( -402.62%)
  • Historical Volatility 112.05%
  • IV Percentile 83%
  • IV Rank 23.15%
  • IV High 1,252.02% on 05/18/22
  • IV Low 39.76% on 02/16/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 12
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 664
  • Open Int (30-Day) 569

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.46
  • Number of Estimates 3
  • High Estimate -0.25
  • Low Estimate -0.73
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +23.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4999 +27.03%
on 06/16/22
0.8299 -23.48%
on 06/02/22
-0.1450 (-18.59%)
since 06/01/22
3-Month
0.4999 +27.03%
on 06/16/22
1.6900 -62.43%
on 04/12/22
-0.5750 (-47.52%)
since 04/01/22
52-Week
0.4999 +27.03%
on 06/16/22
4.1000 -84.51%
on 10/14/21
-3.0150 (-82.60%)
since 07/01/21

Most Recent Stories

More News
10 Penny Stocks with > 1,000% Upside

Rising interest rates, sky-high inflation, and geopolitical concerns have dragged down the S&P 500 (SPX) and NASDAQ Composite (NDX) into bear market territory. While all this sounds rather doom and gloom,...

AMTI : 2.90 (-0.34%)
ANGN : 1.1200 (-1.75%)
CKPT : 1.0500 (+1.94%)
EFTR : 1.3100 (-7.75%)
FRLN : 0.8963 (+3.02%)
GLYC : 0.5634 (-5.77%)
MGNX : 3.05 (+3.39%)
OCUP : 1.8900 (-1.56%)
PHAS : 0.6350 (+5.85%)
PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates

PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of 65.67% and 98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

PHAS : 0.6350 (+5.85%)
PTN : 0.2725 (-2.89%)
PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced...

PHAS : 0.6350 (+5.85%)
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported...

PHAS : 0.6350 (+5.85%)
PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced...

PHAS : 0.6350 (+5.85%)
PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced...

PHAS : 0.6350 (+5.85%)
PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported...

PHAS : 0.6350 (+5.85%)
PhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care Conference

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced...

PHAS : 0.6350 (+5.85%)
PhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at the 2022 American College of Cardiology (ACC.22) Annual Scientific Session

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced...

PHAS : 0.6350 (+5.85%)
PhaseBio Provides Pemziviptadil (PB1046) Program Update

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced...

PHAS : 0.6350 (+5.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company's product consists of PB2452, a novel reversal agent for the antiplatelet...

See More

Key Turning Points

3rd Resistance Point 0.7358
2nd Resistance Point 0.6977
1st Resistance Point 0.6663
Last Price 0.6350
1st Support Level 0.5968
2nd Support Level 0.5587
3rd Support Level 0.5273

See More

52-Week High 4.1000
Fibonacci 61.8% 2.7248
Fibonacci 50% 2.2999
Fibonacci 38.2% 1.8751
Last Price 0.6350
52-Week Low 0.4999

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar